Endometriosis

Reading File
Finding Sources
Searching Images

endometriosis pathology laparoscopy

Now let me read the most authoritative source — Robbins Pathology, which has a dedicated section on endometriosis with multiple paragraphs:
Reading File
Reading File
Reading File
Finding Sources
Reading File
Reading File
Reading File
Reading File
I now have comprehensive information. Let me also fetch the key pathogenesis diagram from Robbins.
Loading Image
Loading Image
Here is a comprehensive overview of endometriosis, synthesized from authoritative textbooks.

Endometriosis

Definition

Endometriosis is defined by the presence of endometrial glands and stroma outside the uterus. It affects up to 10% of women in their reproductive years and nearly half of women with infertility. — Robbins & Kumar Basic Pathology

Classification (Three Types)

TypeDescription
Superficial peritonealImplants on peritoneal surfaces
Ovarian endometriosis"Chocolate cysts" (endometriomas)
Deep infiltrating endometriosis (DIE)Penetrates >5 mm below peritoneum; highest malignant transformation risk

Pathogenesis

The exact mechanism remains elusive. Four leading theories exist:
  1. Regurgitation (Sampson's theory) — Retrograde flow of menstrual endometrium through the fallopian tube implants at ectopic sites (the dominant theory)
  2. Benign metastasis theory — Endometrial tissue spreads hematogenously or via lymphatics to distant sites (lung, bone, brain)
  3. Metaplastic theory — Coelomic (peritoneal) epithelium undergoes metaplasia into endometrial tissue, arising from the same müllerian duct precursors
  4. Extrauterine stem/progenitor cell theory — Bone marrow-derived stem cells differentiate into ectopic endometrial tissue
Once implanted, endometriotic tissue is not merely misplaced endometrium — it actively perpetuates itself through a cycle of inflammation:
Pathogenesis of endometriosis — showing retrograde menstruation, endometriotic implants producing aromatase, PGE2, angiogenic factors, and interaction with activated macrophages (COX2↑) to increase survival of endometrial tissue
FIG. Pathogenesis of endometriosis — Robbins & Kumar Basic Pathology
Key molecular drivers:
  • Aromatase — elevated in endometriotic stromal cells → increased local estrogen production from androgens
  • PGE2 (prostaglandin E2) — proinflammatory, promotes implant survival
  • VEGF — drives angiogenesis to feed the implants
  • MMPs — facilitate tissue invasion
  • Recruited macrophages (COX2↑) amplify the inflammatory cycle

Morphology

Implants appear as red-brown nodules (microscopic to 1–2 cm) on serosal surfaces, caused by cyclic hemorrhage. In widespread disease:
  • Organizing hemorrhage leads to fibrous adhesions between fallopian tubes, ovaries, and pelvic structures
  • The pouch of Douglas may be obliterated
  • Ovarian chocolate cysts (endometriomas) form — cystic masses 3–5 cm filled with old brown blood
Ovarian endometriosis — sectioned ovary with large chocolate cyst containing degenerated blood
Ovarian endometriosis (chocolate cyst) — Robbins & Kumar Basic Pathology
Histologic diagnosis requires identifying both endometrial glands AND stroma at the ectopic site.

Clinical Features

  • Dysmenorrhea (most common symptom)
  • Dyspareunia (painful intercourse)
  • Chronic pelvic pain
  • Infertility (~50% of infertile women)
  • Rectal bleeding (bowel involvement — sigmoid most common, 12–37% of cases)
  • Laparoscopic findings: "powder-burn" lesions, peritoneal implants, dense adhesions, chocolate cysts

Staging (r-ASRM)

Classified I–IV (minimal to severe) based on implant size, adhesions, and involvement of pelvic structures. The Endometriosis Fertility Index (EFI) is a validated tool for predicting post-surgical fertility outcomes.

Treatment

Treatment must be individualized, considering symptom profile, desire for fertility, and disease severity. Endometriosis is a chronic disease with high recurrence after both medical and surgical treatment. — Berek & Novak's Gynecology

1. Analgesics

  • NSAIDs (ibuprofen, naproxen, mefenamic acid) — first-line for dysmenorrhea; inhibit prostaglandin synthase
  • Started at onset of bleeding, continued up to 3 days

2. Hormonal (Medical) Therapy

Goal: suppress ovulation and reduce estrogen-driven implant growth
AgentMechanism
Combined oral contraceptivesSuppress ovulation; continuous use preferred
Progestins (norethindrone 5 mg/day)Decidualization and atrophy of implants
GnRH agonists (e.g., leuprolide)Pituitary downregulation → hypoestrogenic state; often combined with "add-back" HRT to prevent bone loss
DanazolAndrogen/anti-gonadotropin; suppresses implants but androgenic side effects limit use
Medical therapy provides temporary relief — implants recur after treatment cessation.

3. Surgical Treatment

  • Laparoscopy is preferred over laparotomy (equivalent efficacy, faster recovery, less morbidity, fewer adhesions)
  • Laparotomy only for advanced-stage disease where laparoscopy is impossible
  • Goal: excise all visible lesions, lyse adhesions, restore normal anatomy
Peritoneal endometriosis: ablation (coagulation, laser) or excision — both equivalent; excision preferred to allow histologic confirmation
Ovarian endometriomas (≥3 cm): Cystectomy (excision of cyst wall) is preferred over drainage + ablation — lower recurrence of pain, lower endometrioma recurrence, higher spontaneous pregnancy rates (ESHRE guideline)
Deep infiltrating endometriosis: Complete excision in a single procedure at a specialized center with multidisciplinary expertise; asymptomatic patients should NOT undergo surgery unless complete ureteral obstruction with silent renal loss is present

4. Assisted Reproduction

For infertility-associated endometriosis when medical/surgical options are insufficient.

Extrapelvic Manifestations

  • GI tract (12–37%): sigmoid colon most common; serosal implants invade muscularis propria → fibrosis, bowel wall contraction, rectal bleeding; MRI demonstrates low-signal fibrotic plaques obliterating the pouch of Douglas
  • Diaphragm: upper abdominal extrapelvic endometriosis (requires thorough exploration during surgery)
  • Pleura/Lung (rare): catamenial pneumothorax, hemoptysis
  • Surgical scars, umbilicus

Prognosis

  • Disease progresses in 30–60% of patients within a year of diagnosis
  • Recurrence is high after both medical and surgical treatment
  • Risk of malignant transformation is mainly confined to deep infiltrating endometriosis (particularly clear cell and endometrioid carcinoma arising in endometriomas)
  • Referral to a specialized center is strongly recommended for severe or deep endometriosis

Sources: Robbins & Kumar Basic Pathology; Berek & Novak's Gynecology; Goldman-Cecil Medicine; Grainger & Allison's Diagnostic Radiology
This is a shared conversation. Sign in to Orris to start your own chat.